Site icon WBHM 90.3

UAB Looking For A Variety Of Patients For COVID-19 Clinical Trials

University Hospital Sign (UAB)

Infectious disease doctors at UAB said Tuesday they’re still looking for COVID-19 patients to join a number of clinical trials.

Currently, UAB is offering both inpatient and outpatient trials ranging from vaccines to treatments aimed at lessening the effects of the virus.

Dr. Sonya Heath, a professor of medicine in UAB’s Division of Infectious Diseases, said some of the outpatient trials could appeal to patients because they only require a single dose, four in-person visits and virtual check-ins.

One of the trials currently accepting patients involves convalescent plasma treatments, which take antibodies from recovered patients and injects them into patients who have COVID or those who have come into close contact with the virus.

“We are really asking the question: If you give high concentrations of antibody, is that beneficial in decreasing the severity of the illness and decreasing the likelihood that somebody will be hospitalized,” Heath said.

Other studies have shown that patients do better if their bodies generate an immune response to the virus.

“They have a shorter course of illness and their viral load is lower,” Heath said. “We know that generating an immune response is a good thing and decreases your symptoms and severity. Each of these studies … is looking at ways to transfer an immune response to you in some form or fashion.”

Dr. Turner Overton, from UAB’s outpatient COVID-19 clinic, says patients should enroll in clinical trials because it gives them a more heightened level of clinical care.

“We’re gaining knowledge and we have expertise here at UAB,” Overton said. “But if people sit at home and wait until they’re really sick, in the second week of illness, you know, the complications are much higher.”

UAB is looking for COVID-19 patients with varying degrees of symptoms.

Editor’s Note: UAB holds WBHM’s broadcast license but our news and business departments operate independently.

Exit mobile version